Phase I Study of ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer
- The main purpose is to find the highest dose of ZD6474 that is safe to give in
combination with cetuximab and irinotecan. We will also be collecting information on
how the body responds to the study drugs and what effects, good or bad, it has on
treatment of colon and rectal cancer.
- Initially we plan to add ZD6474 to cetuximab alone. Small groups of participants will
be enrolled in steps. The first group will be given a certain dose of ZD6474 and
cetuximab. If the participants have few or manageable side effects, the next small
group of people will receive a higher dose of ZD6474. This increase will continue
until the study doctors find the highest dose that can be given.
- Once we determine the highest dose of ZD6474 with cetuximab, we will add irinotecan at
increasing doses to determine the safety of all three drugs combined. The participant
will know whether they are receiving the two or three drug combination.
- In order to confirm the safety of combining these drugs and to understand more how they
work and interact with each other, some participants on this study will take just the
ZD6474 for 2 weeks prior to starting the cetuximab and/or irinotecan.
- Each cycle of treatment is 8 weeks long. All participants will start taking ZD6474
orally, on day one and continue taking it at home thereafter. Cetuximab and irinotecan
are given intravenously. Cetuximab is given once a week. Irinotecan will be given to
participants that enter the trial once the safe dose of ZD6474 and cetuximab is
determined. Irinotecan is given on Day 15 of cycle one, then every other week.
- Participants will be asked to visit the clinic every week for the first three weeks
they are on the study. After the first three weeks, they will be required to visit
with the doctor every other week. These visits will include physical exams, routine
blood tests, scans, and other tests or procedures to monitor health.
- In addition to routine blood tests, blood tests for research will be done on the last
10 subjects on the trial. Test results from this sample will be used to evaluate the
- In order to be treated on this study, a tumor tissue specimen must ba available for
research testing. The specimen will be taken from a biopsy that was done before the
participant enrolled on the study.
- Participants can continue on the study drug as long as they tolerate the drug and the
cancer does not grow.
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the tolerability and maximum tolerated dose of combining ZD6474, cetuximab and irinotecan in patients with metastatic colorectal cancer refractory to prior cytotoxic chemotherapy.
Jeffrey Meyerhardt, MD
Dana-Farber Cancer Institute
United States: Food and Drug Administration
|Beth Israel Deaconess Medical Center||Boston, Massachusetts 02215|
|Dana-Farber Cancer Institute||Boston, Massachusetts 02115|
|Massachusetts General Hospital||Boston, Massachusetts 02114-2617|